Singapore: Genetic Technologies announced the appointment of Mr. Mark Ostrowski as Senior Vice President Sales and Marketing Molecular Diagnostics. In this role, Mark will be responsible for managing the US sales effort for BREVAGen, the company's cornerstone commercial product.
Mark brings to Genetic Technologies over 20 years of sales and marketing experience in molecular diagnostics having served in senior managerial positions at companies focused on women's health and oncology, including as Director of Sales Operations at Myriad Genetics and Director of Managed Care Services at DIANON Systems.
"On behalf of the management team and Board, I am delighted to welcome Mark to Genetic Technologies. This is an important period for BREVAGen^TM, as the product transitions from its initial pilot commercial phase to a true national program," said Dr. Paul MacLeman, Genetic Technologies' Chief Executive Officer. "Mark's deep knowledge of the diagnostic space and sales managerial leadership will play an integral role in facilitating growth for our flagship product."

Prior to joining Genetic Technologies, Mark's career spanned both early stage and established biomedical companies. During Mark's tenure at Myriad, he had comprehensive exposure to all aspects of sales and marketing, managing a sales force of over 200 representatives, demonstrating average annual revenue growth of over 50%, and generating new strategic divisions and best practice policies.

"I'm excited by the opportunity to join Genetic Technologies and to spearhead BREVAGen's^TM commercialization efforts. I am looking forward to applying my experience in oncology and women's health diagnostics to BREVAGen^TM, which I feel has the potential to be a keystone product in the
evolution of breast health," said Mr. Ostrowski. "The recent approval to sell BREVAGen^TM within the state of California has provided access to a material segment of the U.S. market. With New York and Florida approvals on the horizon, I see a tremendous opportunity to leverage these significant
milestones into increased national adoption for this important test."
With the successful establishment of the Company's U.S. infrastructure over the past two and a half years, culminating in the launch of BREVAGen^TM, the Company is now sharpening the focus of the
U.S. organization around sales and centralizing support activities in Australia. As a result, the leadership of the U.S. sales and marketing group will be transitioning to Mr. Ostrowski. Mr. Lewis Stuart will be assisting the Company in a strategic advisory capacity during this process.